advertisement

Oculus

Abstract #82159 Published in IGR 20-4

Tear neuromediators in eyes on chronic topical antiglaucoma therapy with and without BAK preservatives

Murugesan V; Dwivedi R; Saini M; Gupta V; Dada T; Vivekanandhan S
British Journal of Ophthalmology 2019; 0:


PURPOSE: To evaluate tear neuropeptides (NPs) (vasoactive intestinal peptide (VIP), neuropeptide Y (NPY), calcitonin gene-related peptide (CGRP), substance P (SP), nerve growth factor (NGF)) in chronic ocular topical hypotensive therapy with and without benzalkonium chloride (BAK) preservative. METHODS: A comparative, open label, cross-sectional study of patients using antiglaucoma medications for 6 months with BAK (group I), without BAK (group II) and controls was done. Tear NPs (ELISA), ocular surface evaluation tests (tear breakup time (TBUT), Schirmer's test, corneal and conjunctival staining score) and confocal central corneal subbasal nerve fibre layer (SBNFL) imaging was done. RESULTS: Of 153 eyes evaluated, group 1 (82 eyes (41 patients; mean age 48±14.5 years)) and group 2 (71 eyes (36 patients; mean age 43.11±15 years)) were on therapy for a mean duration of 10.05±2.0 and 9.67±2.3 months, respectively. Tear analysis showed elevated SP and NGF (p<0.01); decreased CGRP (p=0.03), VIP and NPY (p<0.01) compared with controls (n=30, mean age 29.33±5.7 years). Tear NP levels (SP (p=0.1), NGF (p=0.33), CGRP (p=1), VIP (p=0.87), NPY (p=0.83)) and SBNFL (p=0.09) were comparable in both groups. There was no correlation seen between tear NP levels and clinical tests and SBNFL. CONCLUSION: Our study analysis points towards altered tear NP levels in eyes on chronic topical hypotensive therapy in comparison with controls with no significant difference in tear NP levels and central corneal SBNFL density between the BAK preservative and BAK-free antiglaucoma therapy.

Dr R P Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, Delhi, India vanathi_g@yahoo.com.

Full article

Classification:

11.16 Vehicles, delivery systems, pharmacokinetics, formulation (Part of: 11 Medical treatment)
3.7 Biochemistry (Part of: 3 Laboratory methods)
2.1 Conjunctiva (Part of: 2 Anatomical structures in glaucoma)



Issue 20-4

Select Issue


advertisement

Oculus